VC005 tablets for teenagers with vitiligo
Treatments studied
Part of Skin clinical trials.
This trial tests a new medicine, VC005, taken as a tablet, to see if it can help treat vitiligo in teenagers. It may help restore skin color in areas affected by vitiligo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old (turning 18 is not included) and weigh at least 30 kg (about 66 pounds).
- You have been diagnosed with non-segmental vitiligo (a type of vitiligo that usually appears on both sides of the body).
- You are not pregnant or breastfeeding, and you agree not to become pregnant during the study.
- You do not have complete loss of color in the hair within the vitiligo patches.
- You do not have other types of vitiligo or other skin conditions that cause loss of color.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral tablet called VC005 to see if it can help treat non-segmental vitiligo. It may be an option for adults with vitiligo patches that are not limited to one area of the body.
This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.
This trial tests two forms of a drug (SHR0302) for non-segmental vitiligo. One is a pill, the other a gel. The goal is to see if they can repigment the skin with fewer side effects.
This study tests a new drug called EI-001 for people with non-segmental vitiligo (a type where white patches appear on both sides of the body). It is for those whose vitiligo has not gotten better with standard treatments like creams or light therapy, or who cannot use those treatments.
This study tests a new medication called FXS5626 to help treat non-segmental vitiligo (a type of vitiligo that affects both sides of the body). It is for people who have moderate to large patches of vitiligo, especially on the face.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
Hear when a new Non-segmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.